Zealand Pharma A/S (Zealand Pharma A/S) Long-Term Capital Lease Obligation : $14.81 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Long-Term Capital Lease Obligation?

Zealand Pharma A/S's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $14.81 Mil.

Zealand Pharma A/S's quarterly Long-Term Capital Lease Obligation increased from Sep. 2023 ($14.47 Mil) to Dec. 2023 ($15.01 Mil) but then declined from Dec. 2023 ($15.01 Mil) to Mar. 2024 ($14.81 Mil).

Zealand Pharma A/S's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($18.94 Mil) to Dec. 2022 ($15.38 Mil) and declined from Dec. 2022 ($15.38 Mil) to Dec. 2023 ($15.01 Mil).

Zealand Pharma A/S Long-Term Capital Lease Obligation Historical Data

The historical data trend for Zealand Pharma A/S's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Long-Term Capital Lease Obligation Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

11.61

18.98

18.94

15.38

15.01

Zealand Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															15.11	14.85	14.47	15.01	14.81

Zealand Pharma A/S (OTCPK:ZLDPF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Zealand Pharma A/S Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.